264208-45-9

Usage

Uses

Used in Pharmaceutical Industry:
5-(4-Fluoro-phenyl)-2,4-dihydro-pyrazol-3-one is utilized as a key intermediate in the synthesis of pharmaceuticals for various therapeutic applications. Its unique structure and properties make it a valuable component in the development of new drugs targeting a range of health conditions.
Used in Drug Discovery and Development:
In the field of drug discovery and development, 5-(4-Fluoro-phenyl)-2,4-dihydro-pyrazol-3-one serves as a potential lead compound. Its chemical properties and structural features allow researchers to explore its potential as a precursor for the creation of novel therapeutic agents with improved efficacy and safety profiles.
Used in Medicinal Chemistry Research:
5-(4-Fluoro-phenyl)-2,4-dihydro-pyrazol-3-one is employed as a research tool in medicinal chemistry. It aids scientists in understanding the structure-activity relationships of pyrazolone derivatives and their potential interactions with biological targets, thereby contributing to the advancement of drug design and optimization strategies.
Used in Chemical Synthesis:
As a versatile organic compound, 5-(4-Fluoro-phenyl)-2,4-dihydro-pyrazol-3-one is used in chemical synthesis processes. Its reactivity and functional groups enable the formation of various derivatives and analogs, which can be further explored for their potential applications in different industries, including pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 63131-29-3 methyl 4-fluorobenzoyl acetate 

Relevant academic research and scientific papers

QUINAZOLINE DERIVATIVES

The invention relates to the use of compounds of the formula I: wherein: ring C is a 5-6 membered heterocyclic moiety; Z is -O-, -S-, or -CH2-; R1 is hydrogen, C1-4alkyl, C1-4alkoxymethyl, di(C1-4)alkoxy)methyl, C1-4alkanoyl, trifluoromethyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, carboxy, C3-7cycloalkyl, C3-7-cycloalkylC1-3alkyl, or an optionally substituted group selected from phenyl, benzyl, phenylC2-4alkyl and a 5-6 membered heterocyclic group; n is an integer from 0 to 5; m is an integer from 0 to 3; R2 represents hydrogen, hydroxy, halgeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NR3R4 (wherein R3 and R4, which may be the same or different, each represents hydrogen or C1-3alkyl), or R5X1- (wherein X1 represents a direct bond, -CH2-, or a heteroatom linker group and R5 is an alkyl, alkenyl or alkynyl chain optionally substituted by for example hydroxy, amino, nitro, alkyl, cycloalkyl, alkoxyalkyl, or an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring, which alkyl, alkenyl or alkynyl chain may have a heteroatom linker group, or R5 is an optionally substituted group selected from pyridone, phenyl and a heterocyclic ring, and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula I. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.